An anti-cancer compound developed at USA Health Mitchell Cancer Institute is showing promise in pre-clinical studies – one involving pancreatic cancer and the other involving breast cancer. The compound, MCI-715, was developed by Gary Piazza, Ph.D., and his lab team at the Drug Discovery Research Center at MCI.
About Your Visit
Maybe you're planning to visit a friend or family member who is in the hospital. Maybe you want to accompany them on an office visit. Or you may be interested in supporting our healthcare mission by becoming a volunteer. Whatever the case, we try to provide answers to the many questions you may have about USA Health.